News & Events
Disc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline
Company welcomes Dr. Hua Yang, PhD, as VP, Nonclinical Development and Clinical Pharmacology and Sarah Tuller, JD as VP, Regulatory Affairs CAMBRIDGE, Mass. (August 23, 2021) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for
More News
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
WATERTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more
Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update
Presented positive initial safety and efficacy data from the BEACON trial at the European Hematology Association (EHA) Congress in June 2023; data...
read more